Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease
Acta Neuropathologica · 2025
DOI: 10.1007/s00401-025-02890-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Neuropathologica, 2025. Verfasst von Charles D Chen und 49 weiteren Autor:innen. Beteiligte Einrichtung: Washington University in St. Louis, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Alzheimer Disease, Brain. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIH HHS, NCRR NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Clinical trials of anti-amyloid-β (Aβ) monoclonal antibodies in Alzheimer disease (AD) infer target engagement from Aβ positron emission tomography (PET) and/or fluid biomarkers such as cerebrospinal fluid (CSF) Aβ42/40. However, these biomarkers measure brain Aβ deposits indirectly and/or incompletely. In contrast, neuropathologic assessments allow direct investigation of treatment effects on brain Aβ deposits-and on potentially myriad 'downstream' pathologic features. From a clinical trial of anti-Aβ monoclonal antibodies in dominantly inherited AD (DIAD), in the largest study of its kind, we measured immunohistochemistry area fractions (AFs) for Aβ deposits (10D5), tauopathy (PHF1), microgliosis (IBA1), and astrocytosis (GFAP) in 10 brain regions from 10 trial cases-gantenerumab (n = 4), solanezumab (n = 4), placebo/no treatment (n = 2)-and 10 DIAD observational study cases. Strikingly, in proportion to total drug received, Aβ deposit AFs were significantly lower in the gantenerumab arm versus controls in almost all areas examined, including frontal, temporal, parietal, and occipital cortices, anterior cingulate, hippocampus, caudate, putamen, thalamus, and cerebellar gray matter; only posterior cingulate and cerebellar white matter comparisons were non-significant. In contrast, AFs of tauopathy, microgliosis, and astrocytosis showed no differences across groups. Our results demonstrate with direct histologic evidence that gantenerumab treatment in DIAD can reduce parenchymal Aβ deposits throughout the brain in a dose-dependent manner, suggesting that more complete removal may be possible with earlier and more aggressive treatment regimens. Although AFs of tauopathy, microgliosis, and astrocytosis showed no clear response to partial Aβ removal in this limited autopsy cohort, future examination of these cases with more sensitive techniques (e.g., mass spectrometry) may reveal more subtle 'downstream' effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Washington University in St. Louis, St. Louis, MO, USA.
- Massachusetts General Hospital, Boston, MA, USA.
- Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
- The University of British Columbia, Vancouver, BC, Canada.
- McGill University, Montreal, QC, Canada.
- University of Pittsburgh, Pittsburgh, PA, USA.
Förderung
- NIA NIH HHS
- NIH HHS
- NCRR NIH HHS
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Chen, C. D., Franklin, E. E., Li, Y., Joseph-Mathurin, N., Burns, A. L., Hobbs, D. A., McCullough, A. A., Schultz, S. A., Xiong, C., Wang, G., Masellis, M., Hsiung, G. R., Gauthier, S., Berman, S. B., Roberson, E. D., Honig, L. S., Clarnette, R., Ringman, J. M., Galvin, J. E., …, & DIAN-Obs Study Team (2025). Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-025-02890-7
Vancouver
Chen CD, Franklin EE, Li Y, Joseph-Mathurin N, Burns AL, Hobbs DA, et al. Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease. Acta Neuropathologica. 2025. doi:10.1007/s00401-025-02890-7
BibTeX
@article{Chen2025,
author = {Chen, Charles D and Franklin, Erin E and Li, Yan and Joseph-Mathurin, Nelly and Burns, Aime L and Hobbs, Diana A and McCullough, Austin A and Schultz, Stephanie A and Xiong, Chengjie and Wang, Guoqiao and Masellis, Mario and Hsiung, Ging-Yuek Robin and Gauthier, Serge and Berman, Sarah B and Roberson, Erik D and Honig, Lawrence S and Clarnette, Roger and Ringman, John M and Galvin, James E and Brooks, William and Suzuki, Kazushi and Black, Sandra and Levin, Johannes and Aggarwal, Neelum T and Jucker, Mathias and Frosch, Matthew P and Kofler, Julia K and White, Charles and Keene, C Dirk and Chen, Jie and Daniels, Alisha and Gordon, Brian A and Ibanez, Laura and Karch, Celeste M and Llibre-Guerra, Jorge and McDade, Eric and Morris, John C and Supnet-Bell, Charlene and Allegri, Ricardo F and Lee, Jae-Hong and Day, Gregory S and Lopera, Francisco and Roh, Jee Hoon and Schofield, Peter R and Mills, Susan and Benzinger, Tammie L S and Bateman, Randall J and Perrin, Richard J and DIAN-TU Study Team, DIAN-TU Study Team and DIAN-Obs Study Team, DIAN-Obs Study Team},
title = {Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease},
journal = {Acta Neuropathologica},
year = {2025},
doi = {10.1007/s00401-025-02890-7}
}
EUVIMED